10x Genomics (TXG) Financial Analysis & Valuation | Quarter Chart
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluid... more
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $9.32B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Healthcare Information Services |
| Country | US | CEO | Serge Saxonov |
| IPO Date | 2019-09-12 | CAGR | 31.69% |
| Employees | 1,178 | Website | www.10xgenomics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TXG chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $8.09B | P/E | -121.27 | Forward P/E | 220.64 | PEG | 0.17 |
| P/S | 180042676677.59 | P/B | 137830564401.51 | P/CF | 890813704869.32 | P/FCF | 910210460769.88 |
| Sales | $616.91M | Sales 1Y | -4.28% | Sales 3Y | 8.53% | Sales 5Y | 52.06% |
| EPS | $-0.59 | EPS 1Y | -15.71% | EPS 3Y | -60.4% | EPS 5Y | -87.53% |
| Sales QoQ | 0.13% | EPS QoQ | 40% | Sales QoQ Avg | -2.85% | EPS QoQ Avg | -50.64% |
| Gross Margin | 70.03% | Operating Margin | -14.33% | Profit Margin | -12.18% | ROCE | -9.7% |
| ROA | -7% | ROE | -9% | Altman Z Score | 26.47 | Piotroski Score | 3 |
| Current Ratio | 5.69 | Quick Ratio | 5.25 | Cash Ratio | 4.24 | Op. CF Ratio | 0.22 |
| Debt/Equity | 0.1 | Debt/Assets | 0.08 | Lt Debt/Equity | 0.08 | Lt Debt/Cap. | 0.07 |
| Intrst Cov. | -29461.33 | Inventory Turnover | 3.51 | Asset Turnover | 0.6 | Receivables Turnover | 12.18 |
| Enterprise Value | $8.09B | P/E Ratio | -121.27 |
| Forward P/E | 220.64 | PEG Ratio | 0.17 |
| P/S Ratio | 180042676677.59 | P/B Ratio | 137830564401.51 |
| P/CF Ratio | 890813704869.32 | P/FCF Ratio | 910210460769.88 |
| EPS | $-0.59 | EPS Growth 1Y | -15.71% |
| EPS Growth 3Y | -60.4% | EPS Growth 5Y | -87.53% |
| Revenue Growth 1Y | -4.28% | Gross Margin | 70.03% |
| Operating Margin | -14.33% | Profit Margin | -12.18% |
| ROE | -9% | ROA | -7% |
| ROCE | -9.7% | Current Ratio | 5.69 |
| Quick Ratio | 5.25 | Cash Ratio | 4.24 |
| Debt/Equity | 0.1 | Interest Coverage | -29461.33 |
| Altman Z Score | 26.47 | Piotroski Score | 3 |
10x Genomics (TXG) valuation & financials
10x Genomics (TXG) has a market capitalization of $9.32B and trades at a price-to-earnings ratio of -121.3. It operates in the Healthcare sector (Medical - Healthcare Information Services).
10x Genomics's revenue grew -4.3% over the last year.
10x Genomics's next earnings report is scheduled for November 5, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.26. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)